-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Gh6MS8QTHH6xa+U1NprF16cGIEPeK/B+22Va5VGVI0s6wQlVZj985ER80F8uAeqg pacEO8uwajvL8mLG31jFMQ== 0000739944-99-000013.txt : 19990817 0000739944-99-000013.hdr.sgml : 19990817 ACCESSION NUMBER: 0000739944-99-000013 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 19990630 FILED AS OF DATE: 19990816 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MEDTOX SCIENTIFIC INC CENTRAL INDEX KEY: 0000739944 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 953863205 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: SEC FILE NUMBER: 001-11394 FILM NUMBER: 99693008 BUSINESS ADDRESS: STREET 1: 402 WEST COUNTY ROAD D CITY: ST PAUL STATE: MN ZIP: 55112 BUSINESS PHONE: 6126367466 MAIL ADDRESS: STREET 1: 402 WEST COUNTY ROAD D CITY: ST PAUL STATE: MN ZIP: 55112 FORMER COMPANY: FORMER CONFORMED NAME: EDITEK INC DATE OF NAME CHANGE: 19940902 FORMER COMPANY: FORMER CONFORMED NAME: ENVIRONMENTAL DIAGNOSTICS INC DATE OF NAME CHANGE: 19920703 10-Q 1 FORM 10-Q FOR PERIOD ENDING JUNE 30, 1999 FORM 10-Q SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) (X) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 1999 OR ( ) TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period to Commission file number 1-11394 MEDTOX SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 95-3863205 (State or other jurisdiction of (I.R.S. Employer incorporated or organization) Identification No.) 402 West County Road D, St.Paul, Minnesota 55112 - ------------------------------------------------------------------------------- (Address of principal executive offices) (Zip Code) Registrant's telephone number including area code: (651) 636-7466 - ------------------------------------------------------------------------------- Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes X No The number of shares of Common Stock, $.15 par value, outstanding as of August 13, 1999, was 2,903,278. MEDTOX SCIENTIFIC, INC. INDEX Page Part I Financial Information: Item 1: Financial Statements Consolidated Balance Sheets - June 30, 1999 (Unaudited) and December 31, 1998 ...................... 3 Consolidated Statements of Operations - Three Months Ended June 30, 1999 and 1998 and Six Months Ended June 30, 1999 and 1998 (Unaudited)......... 5 Consolidated Statements of Cash Flows - Six Months Ended June 30, 1999 and 1998 (Unaudited)......... 6 Notes to Consolidated Financial Statements............... 7 Item 2: Management's Discussion and Analysis of Financial Condition and Results of Operations ....... ..... 11 Part II Other Information .......................................... 19 Signatures .............................................. 20 MEDTOX SCIENTIFIC, INC. CONSOLIDATED BALANCE SHEETS (In thousands, except for number of shares) (Unaudited)
June 30 December 31 1999 1998 Assets Current assets Cash and cash equivalents $ - $ - Accounts receivable: Trade, less allowance for doubtful accounts ($246-1999; $245-1998) 7,397 5,957 Other 60 30 ------------------------------------ 7,457 5,987 Inventories: Raw materials 462 444 Work in process 168 151 Finished goods 89 80 Supplies 503 432 ------------------------------------ 1,222 1,107 Prepaid expenses and other 728 524 ------------------------------------ Total current assets 9,407 7,618 Equipment and improvements: Furniture and equipment 12,285 11,779 Leasehold improvements 1,305 1,283 ------------------------------------ 13,590 13,062 Less accumulated depreciation and amortization (10,793) (10,087) ------------------------------------ 2,797 2,975 Goodwill, net of accumulated amortization of $3,492 in 1999 and $3,086 in 1998 13,601 14,007 ------------------------------------ Total assets $ 25,805 $ 24,600 ====================================
MEDTOX SCIENTIFIC, INC. CONSOLIDATED BALANCE SHEETS (In thousands, except for number of shares) (Unaudited)
June 30 December 31 1999 1998 ------------------------------------ Liabilities and stockholders' equity Current liabilities Line of credit $ 4,482 $ 3,095 Checks written in excess of bank balances 58 142 Accounts payable 2,727 3,531 Accrued expenses 1,700 1,724 Current portion of restructuring accrual 734 1,079 Current portion of long-term debt 1,480 1,140 Current portion of capital lease obligations 186 186 ------------------------------------ Total current liabilities 11,367 10,897 Long-term portion of restructuring accrual - 76 Capital lease obligations 404 516 Long term debt obligations 1,774 1,785 Stockholders' equity Preferred Stock, $1.00 par value: Authorized - 1,000,000 shares; Issued and outstanding - none in 1999 and none in 1998 - - Common Stock, $ .15 par value: Authorized - 3,750,000 shares; Issued and outstanding - 2,903,236 shares in 1999 and 2,899,669 shares in 1998 437 435 Additional paid-in capital 59,845 59,815 Accumulated deficit (47,846) (48,748) Treasury stock (176) (176) ------------------------------------ Total stockholders' equity 12,260 11,326 ------------------------------------ Total liabilities and stockholders' equity $ 25,805 $ 24,600 ====================================
MEDTOX SCIENTIFIC, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except share and per share data) (Unaudited)
Three Months Ended Six Months Ended June 30 June 30 1999 1998 1999 1998 Revenues Laboratory service revenues $ 8,210 $ 7,307 $ 15,260 $ 13,854 Product sales 942 599 1,727 1,131 ----------------------------- ---------------------- 9,152 7,906 16,987 14,985 Cost of services 5,386 4,878 10,225 9,278 Cost of sales 549 413 956 765 ---------------------------- ---------------------- 5,935 5,291 11,181 10,043 Gross profit 3,217 2,615 5,806 4,942 Operating expenses Selling, general and administrative 2,254 1,867 4,274 3,669 Research and development 187 288 420 595 Interest and financing costs 199 177 375 317 Other non-recurring (164) - (164) - ---------------------------- ---------------------- 2,476 2,332 4,905 4,581 ---------------------------- ---------------------- Net income 741 283 901 361 ---------------------------- ---------------------- ---------------------------- ---------------------- Basic net earnings per common share $ 0.26 $ 0.10 $ 0.31 $ 0.12 ---------------------------- ---------------------- ---------------------------- ---------------------- Diluted net earnings per common share $ 0.25 $ 0.10 $ 0.31 $ 0.12 ============================= ====================== (1) Income per share for the three months ended June 30, 1998 and the six months ended June 30, 1998 has been restated to reflect a one-for-twenty reverse stock split in February, 1999
MEDTOX SCIENTIFIC, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) (Unaudited)
Six Months Ended June 30 June 30 1999 1998 ------------------------------------ Operating activities Net income $ 901 $ 361 Adjustments to reconcile net income to net cash used in operating activities: Depreciation and amortization 1,113 1,027 Changes in operating assets and liabilities; Accounts receivable (1,470) (1,080) Inventories (115) (44) Prepaid expenses and other (204) (78) Accounts payable, accrued expenses and other (827) (481) Restructuring accruals (421) (107) ------------------------------------ Net cash used in operating activities (1,023) (402) Investing activities Purchases of equipment and improvements (529) (677) Financing activities Checks in excess of bank balance (84) - Net proceeds from sale of common stock 2 12 Net proceeds from line of credit, term loans and notes payable 19,061 6,290 Principal payments on capital lease obligations (112) (94) Principal payments on line of credit, term loans and notes payable (17,315) (5,131) ------------------------------------ Net cash provided by financing activities 1,552 1,077 ------------------------------------ Increase in cash and cash equivalents - (2) Cash and cash equivalents at beginning of period - 58 ------------------------------------ Cash and cash equivalents at end of period $ - $ 56 ==================================== Supplemental noncash activities During 1999, the Company entered into capital lease obligations totaling $58,300.
MEDTOX SCIENTIFIC, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 1999 NOTE A -- BASIS OF PRESENTATION The accompanying unaudited consolidated financial statements of MEDTOX Scientific, Inc. (the "Company") have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by generally accepted accounting principles. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of financial condition and results of operations have been included. Operating results for the six-month period ended June 30, 1999 are not necessarily indicative of the results that may be attained for the entire year. These consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 1998. The Company's stockholders approved a one-for-twenty reverse stock split effective February 23, 1999. All stock options, warrant, share and per share data included in this report reflect the effect of this reverse split. Basic earnings per share is computed on the basis of the weighted average number of common shares outstanding. Diluted earnings per share is computed on the basis of the weighted average number of common shares outstanding plus the effect of outstanding stock options using "treasury stock" method.
Three months ended Six months ended June 30 June 30 1999 1998 1999 1998 Net Income (A) $741,000 $283,000 $901,000 $361,000 Weighted average number of shares of common stock outstanding (B) 2,903,502 2,897,033 2,902,414 2,888,666 Dilutive effect of stock options 30,386 0 23,193 0 Common stock and common stock equivalents (C) 2,933,888 2,897,033 2,925,607 2,888,666 Net income per share: Basic (A/B) $.26 $.10 $.31 $.12 Diluted (A/C) $.25 $.10 $.31 $.12
Reclassifications: Certain reclassifications have been made to the 1998 financial statements to conform with 1999 presentation. Comprehensive Income: Comprehensive income is a measure of all nonowner changes in stockholders' equity and includes such items as net income, certain foreign currency translation items, minimum pension liability adjustments, and changes in the value of available-for-sales securities. For the six months ended June 30, 1999 and 1998, comprehensive income for the Company was equivalent to net income as reported. Accounting for Derivatives: In June 1997 the Financial Accounting Standards Board released SFAS No. 133 "Accounting for Derivatives Instruments and Hedging Activities", which will be effective for the company beginning January 1, 2000. SFAS No. 133 establishes new accounting reporting standards for derivative instruments, including certain derivative instruments embedded in other contracts, and for hedging activities. The Company has not yet completed its analysis of the effect, if any, this standard will have on future operating results. NOTE B - DEBT On January 14, 1998, the Company entered into a Credit Security Agreement (the "Wells Fargo Credit Agreement" f/k/a "Norwest Credit Agreement") with Wells Fargo Business Credit (Wells Fargo), f/k/a Norwest Business Credit. The Wells Fargo Credit Agreement consists of (i) a term loan of $2,125,000, (ii) a term loan of $700,000, (iii) a revolving line of credit based upon the balance of the Company's trade accounts receivable, and (iv) a note of up to $1,200,000 for the purchase of capital equipment for 1998. The term loan of $2,125,000 carries an interest rate equal to 1.25% above the publicly announced rate of interest by Wells Fargo Bank Minnesota, N.A. (the "Base Rate"). The $700,000 term loan has an interest rate equal to 3.00% above the Base Rate as does the line of credit. The note for the capital expenditures carries an interest rate equal to 1.25% above the Base Rate. The Company utilized $4.5 million of the proceeds received from Wells Fargo to pay off the outstanding loan balance owed to its former lender. On November 24, 1998 the Company and Wells Fargo Business Credit amended the Credit Agreement. The amended Wells Fargo Credit Agreement consists of (i) an increase in the remaining balance on the term loan to the original amount of $2,125,000, (ii) an increase in the remaining balance on the $700,000 term loan to $417,000, and (iii) a note of up to $1,000,000 for the purchase of capital equipment for 1999. On June 4, 1999 the Company and Wells Fargo Business Credit amended the Credit Agreement. The amended Wells Fargo Credit Agreement consists of an increase in the $700,000 term loan to the original amount of $700,000. As of June 30, 1999 the $2,125,000 term loan carried a balance of $1,712,000; the $700,000 term loan carried a balance of $700,000; the revolving line of credit balance was $4,482,000; and the balance on the capital equipment note was $309,000. As of December 31, 1998, the Company was not in compliance with certain covenants of the Wells Fargo Credit Agreement. However, on April 12, 1999, the Company amended the Wells Fargo Credit Agreement (the Third Amendment). The Third Amendment waived the Company's noncompliance with these covenants at December 31, 1998, increased the limit on the note for the purchase of capital equipment from $1,000,000 to $1,400,000 and also modified the terms of the financial covenants for 1999. As of June 30, 1999 the Company was in compliance with the covenants of the Wells Fargo Credit Agreement as modified by the Third Amendment. At June 30, 1999, the Company had received $575,000 ($400,000 of which was received during the first quarter of 1999) from private placements of subordinated debt, with a maturity date of March 31, 2001. The debt carries an interest rate of 12% and has accompanying warrants to purchase a number of shares of common stock equal to 25% of the notes purchased at an exercise price of $5.50 per share. The Company has determined the value of the warrants at the date of the grants to be $28,500. The value of the warrants has been accounted for as additional paid-in capital and deducted from the principal of the subordinated notes as discount on debt issued. The funds received from the amendment to the Wells Fargo Credit Agreement and the private placements of subordinated debt were used to fund the working capital needs of the Company. NOTE C - SEGMENTS The Company adopted SFAS No. 131, Disclosures about Segments of an Enterprise and Related Information, in 1998, which changes the way the Company reports information about its operating segments. The information for 1998 has been restated to conform to the 1999 presentation. The Company has two reportable segments: Product Sales and Lab Services. The Product Sales segment is made up entirely of MEDTOX Diagnostics. Products manufactured include easy to use, inexpensive, on-site drug tests such as PROFILE II, EZ-SCREEN, EZ-QUANT, and VERDICT. The Lab Services segment includes MEDTOX Laboratories and CMS. Services provided include forensic toxicology, clinical toxicology, heavy metals analyses, courier delivery, and medical surveillance. In evaluating financial performance, management focuses on net income as a segment's measure of profit or loss.
Segment Information (In thousands) Three months ended Six months ended June 30 June 30 Laboratory Services: 1999 1998 1999 1998 Net Sales 8,210 7,307 15,260 13,854 Segment Income(Loss) 710 500 943 796 Product Sales: 1999 1998 1999 1998 Net Sales 942 599 1,727 1,131 Segment Income(Loss) 31 (217) (42) (435) Total: 1999 1998 1999 1998 Net Sales 9,152 7,906 16,987 14,985 Income(Loss) 741 283 901 361
NOTE D - CONTINGENCIES In February, 1999 the Company settled a claim of patent infringement brought against the Company by United States Drug Testing Laboratories on August 20, 1996. It was alleged that the Company infringes two patents allegedly owned by United States Drug Testing Laboratories relating to forensically acceptable determinations of gestational fetal exposure to drugs and other chemical agents. The Company while denying any infringement has settled with United States Drug Testing Laboratories and has paid United States Drug Testing Laboratories $17,500 and issued United States Drug Testing Laboratories 2,500 shares of common stock valued at $12,500. The Company had previously accrued for this contingency. Accordingly, the settlement of this matter did not effect results of operations during the three months and the six months ended June 30, 1999. Under the MEDTOX Laboratories acquisition agreement, the sellers of MEDTOX Laboratories, remain liable for any and all damages awarded for any infringement which may have occurred on or before the closing date of the Purchase Agreement. The Purchase Agreement also provides for the seller to indemnify and hold the Company harmless from and against any damages, loss, liability or expense, including reasonable attorneys' fees and court cost in connection with any infringement which may have occurred on or before the closing date. The company is seeking to recover $79,000 in damages from the sellers in accordance with these provisions of the Purchase Agreement for legal fees and settlement cost relating to the United States Drug Testing Laboratories claim. On January 31, 1997, the Company filed suit in Federal District Court in Minnesota against Morgan Capital LLC, David Bistricer and Alex Bistricer alleging violation in Section 16(b) of the Securities and Exchange Act of 1934 and seeking recovery of more than $500,000 in short-swing profits. Messrs. David and Alex Bistricer are former directors of the Company. On August 4, 1997, the U.S. District Court granted Defendants' motion to dismiss the Company's complaint, ruling that the Defendants' conduct did not constitute a violation of Section 16(b). On October 29, 1997, the Company filed an appeal of that decision to the United States Court of Appeals for the Eighth Circuit. On July 21, 1998, the Eighth Circuit reversed the District Court dismissal and remanded the case to the District Court. On June 3, 1999, the United States District Court for the District of Minnesota ruled in favor of the Company in its claim against Morgan Capital LLC. The Court found that Morgan Capital had violated Section 16(b) and ordered Morgan Capital to pay the Company damages of $551,000 plus interest. The Company believes it is likely that Morgan Capital will appeal the decision to the 8th Circuit U.S. Court of Appeals. In May, 1999 the Company settled a lawsuit in the Circuit Court of Cook County, Illinois. The suit was brought by a previous landlord who alleged that the Company breached the terms of a lease in connection with the asset acquisition of MEDTOX Laboratories. In December 1998, the Court had granted summary judgment against the Company on the issue of liability. The Company settled this matter for $684,965. The Company had previously accrued $850,000 for this contingency. Item 2: MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Cautionary Statement Identifying Important Factors That Could Cause the Company's Actual Results to Differ From Those Projected in Forward Looking Statements In connection with the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, readers of this document and any document incorporated by reference herein, are advised that this document and documents incorporated by reference into this document contain both statements of historical facts and forward looking statements. Forward looking statements are subject to certain risks and uncertainties, which could cause actual results to differ materially from those indicated by the forward looking statements. Examples of forward looking statements include, but are not limited to (i) projections of revenues, income or loss, earnings or loss per share, capital expenditures, dividends, capital structure and other financial items, (ii) statements of the plans and objectives of the Company or its management or Board of Directors, including the introduction of new products, or estimates or predictions of actions by customers, suppliers, competitors or regulatory authorities, (iii) statements of future economic performance, and (iv) statements of assumptions underlying other statements and statements about the Company or its business. This document and any documents incorporated by reference herein also identify important factors which could cause actual results to differ materially from those indicated by the forward looking statements. These risks and uncertainties include price competition, the decisions of customers, the actions of competitors, the effects of government regulation, possible delays in the introduction of new products, customer acceptance of products and services, the possible effects of the MEDTOX acquisition and its related financings and other factors which are described herein and/or in documents incorporated by reference herein. The cautionary statements made pursuant to the Private Litigation Securities Reform Act of 1995 above and elsewhere by the Company should not be construed as exhaustive or as any admission regarding the adequacy of disclosures made by the Company prior to the effective date of such Act. Forward looking statements are beyond the ability of the Company to control and in many cases the Company cannot predict what factors would cause results to differ materially from those indicated by the forward looking statements. Introduction MEDTOX Scientific, Inc. and its subsidiaries, MEDTOX Laboratories, Inc. and MEDTOX Diagnostics, Inc., are referred to herein as "the Company". MEDTOX Laboratories, Inc. is a toxicology laboratory which was founded in 1984 and provides forensic toxicology, clinical toxicology, and heavy metals analyses. MEDTOX Diagnostics, Inc. develops, manufactures and markets on-site diagnostic and screening tests which are used to detect substances in humans, foodstuffs, animals, feed and the environment. The company is continuing to transition these operating units from being providers of high quality testing services and devices into a broader service organization by supporting underlying laboratory analysis and point-of-care devices with logistics management, data management and overall program management services. The Company has two reportable segments: laboratory services and product sales. Laboratory services include forensic toxicology, clinical toxicology, and heavy metal analyses as well as logistics, data, and overall program management services. Product sales include a variety of on-site screening products. The Company commenced operations as Environmental Diagnostics, Inc. in June 1983 and until 1986 was a development stage company. The Company became engaged in the manufacture and sale of Conventional Biodiagnostic Products as a result of its acquisition of Granite Technological Enterprises, Inc. in 1986. The Company entered the laboratory testing market when it completed the acquisition of Princeton Diagnostic Laboratories of America, Inc., (PDLA) in 1994. On January 30, 1996 the Company, then known as EDITEK, Inc., completed the acquisition of MEDTOX. In 1997, the Company changed its name to MEDTOX Scientific, Inc. Three Months Ended June 30, 1999 Compared to Three Months Ended June 30, 1998 Laboratory Services Revenues from Laboratory Services for the three months ended June 30, 1999 were $8,210,000 as compared to $7,307,000 for the three months ended June 30, 1998. The increase of $903,000 or 12.4% was primarily attributable to an 8.8% increase in laboratory samples and an increase in average revenue per sample from value added services. The gross margin from the revenues generated from the laboratory services was 34.4% for the three months ended June 30, 1999 as compared to a gross margin of 33.2% for the same period in 1998. The increase in gross margin is primarily attributable to improved efficiencies from higher sample volume and increased revenue from value added services. Selling, general and administrative expenses for the three months ended June 30, 1999 were $2,009,000 compared to $1,650,000 for the three months ended June 30, 1998. The increase of $359,000 or 21.8% in 1999 was primarily the result of increased sales expenses. As a percentage of sales, selling, general and administrative expenses were 24.5% for the three months ended June 30, 1999 compared to 22.6% for the same period in 1998. Research and development expenses incurred during the three months ended June 30, 1999 were $84,000 as compared to $132,000 for the same period in 1998. This decrease of $48,000 was primarily the result of a decrease in personnel costs. The Laboratory Services segment for the three months ended June 30, 1999 incurred interest and financing costs of $183,000, compared to costs of $148,000 incurred during the three months ended June 30, 1998 primarily as a result of higher debt levels. As a result of the above, the net income for the Laboratory Services segment of the Company for the three months ended June 30, 1999 was $710,000, compared to the net income of $500,000 for the three months ended June 30, 1998. Product Sales Revenues from Product Sales for the three months ended June 30, 1999 increased 57.3% to $942,000 as compared to $599,000 for the three months ended June 30, 1998. The increase was attributable to increased sales in all product sales areas. Product sales from substance abuse testing products, which incorporates the EZ-SCREEN PROFILE(R)-II and VERDICT(R)-II on-site test kits and other ancillary products for the detection of abused substances, increased 90.8% to $561,000 for the three months-ended June 30,1999 compared to sales of $294,000 in 1998. The increase in product sales is primarily due to a strong response to the introduction of the Company's second-generation test kits, PROFILE(R)- II and VERDICT(R)- II. The Company is continuing to develop new products in this area and plans to introduce its Emergency Room (ER) panel in the first quarter of 2000. Product sales from agricultural diagnostic products increased 7.6% to $71,000 for the three months ended June 30, 1999 compared to $66,000 in 1998. The primary reason for the increase of $5,000 was the result of increased purchases by the USDA for the Company's products. The USDA's needs for the company's products vary from quarter to quarter and sales to the USDA are expected to fluctuate accordingly. Sales of contract manufacturing services, microbiological and associated products increased 30.1% to $310,000 for the three months ended June 30, 1999 compared to $239,000 in 1998. This increase was due to increased revenues from both historical customers and new customers added in late 1998. Gross margins from Product Sales for the three months ended June 30, 1999 were 41.8% compared to 31.1% for the three months ended June 30, 1998. The increase in gross margin from product sales was due to higher overall sales of products. Selling, general and administration expenses for Products Sales during the three months ended June 30, 1999 were $245,000 compared to $217,000 for the three months ended June 30, 1998. The increase of $28,000 or 12.9% was primarily the result of increased costs associated with higher sales volume. Research and development expenses incurred for Product Sales during the three months ended June 30, 1999 were $103,000 as compared to $156,000 for the same period in 1998. The decrease of $53,000 or 34.0% was primarily the result of completion of the development of the Company's Profile(R)-II new generation on-site product. For the three months ended June 30, 1999, the Product Sales segment incurred interest and financing costs of $16,000 compared to $29,000 during the three months ended June 30, 1998. The decrease was the result of lower borrowings by the Company. As a result of the above, the Product Sales segment net income for the three months ended June 30, 1999 was $31,000, compared to the net loss of ($217,000) for the three months ended June 30, 1998. Six Months Ended June 30, 1999 Compared to Six Months Ended June 30, 1998 Laboratory Services Revenues from Laboratory Services for the six months ended June 30, 1999 were $15,260,000 as compared to $13,854,000 for the six months ended June 30, 1998. The increase of $1,406,000 or 10.1% was primarily attributable to an 8.5% increase in laboratory samples and an increase in average revenue per sample from value added services. The gross margin from the revenues generated from the laboratory services was 33.0% for the six months ended June 30, 1999 as compared to a gross margin of 33.0% for the same period in 1998. Selling, general and administrative expenses for the six months ended June 30, 1999 were $3,748,000 compared to $3,188,000 for the six months ended June 30, 1998. The increase of $560,000 or 17.6% in 1999 was primarily the result of increased depreciation expense, and increased sales expense. As a percentage of sales, selling, general and administrative expenses were 24.5% for the six months ended June 30, 1999 compared to 23.0% for the same period in 1998. Research and development expenses incurred during the six months ended June 30, 1999 were $164,000 as compared to $304,000 for the same period in 1998. This decrease of $140,000 was primarily the result of a decrease in personnel costs. The Laboratory Services segment for the six months ended June 30, 1999 incurred interest and financing costs of $342,000, compared to costs of $288,000 incurred during the six months ended June 30, 1998. The increase was primarily as a result of higher debt levels. As a result of the above, the net income for the Laboratory Services segment of the Company for the six months ended June 30, 1999 was $943,000, compared to the net income of $796,000 for the six months ended June 30, 1998. Product Sales Revenues from Product Sales for the six months ended June 30, 1999 increased 52.7% to $1,727,000 as compared to $1,131,000 for the six months ended June 30, 1998. The increase was attributable to increased sales in all product sales areas. Product sales from substance abuse testing products, which incorporates the EZ-SCREEN PROFILE(R)-II and VERDICT(R)-II on-site test kits and other ancillary products for the detection of abused substances, increased 65.8% to $1,008,000 for the six months ended June 30, 1999 compared to sales of $608,000 in 1998. The increase in product sales is primarily due to a strong response to the introduction of the Company's second-generation test kit, PROFILE(R)- II. Product sales from agricultural diagnostic products increased 50.7% to $226,000 for the six months ended June 30 1999 compared to $150,000 in 1998. The primary reason for the increase of $76,000 was the result of increased purchases by the USDA for the Company's products. The USDA's needs for the company's products vary from quarter to quarter and sales to the USDA are expected to fluctuate accordingly. Sales of contract manufacturing services, microbiological and associated products increased 31.9% to $492,000 for the six months ended June 30, 1999 compared to $373,000 in 1998. This increase was due to increased revenues from both historical customers and new customers added in late 1998. Gross margins from Product Sales for the six months ended June 30, 1999 were 44.6% compared to 32.4% for the six months ended June 30, 1998. The increase in gross margin from product sales was due to higher overall sales of products. Selling, general and administration expenses for Products Sales during the six months ended June 30, 1999 were $526,000, compared to $481,000 for the six months ended June 30, 1998. The increase of $45,000 or 9.4% was primarily the result of increased costs associated with higher sales volume. Research and development expenses incurred for Product Sales during the six months ended June 30, 1999 were $256,000 as compared to $291,000 for the same period in 1998. The decrease of $35,000 or 12.0% was primarily the result of completed development of the Company's Profile (R)-II on-site product. For the six months ended June 30, 1999, the Product Sales segment incurred interest and financing costs of $33,000 as compared to $29,000 for the same period in 1998. The increase of $4,000 or 13.8% was primarily the result of increased debt levels. The interest and finance costs were the result of the funds borrowed by the Company to fund asset purchases and working capital requirements. As a result of the above, the Product Sales segment net loss for the six months ended June 30, 1999 was ($42,000), compared to the net loss of ($435,000) for the six months ended June 30, 1998. Material Changes in Financial Condition Laboratory Services As of June 30, 1999 net accounts and notes receivable for Laboratory Services were $6,785,000 compared to $5,554,000 at December 31, 1998. This increase of $1,231,000 or 22.2% was primarily the result of higher sales for the quarter ended June 30, 1999 as compared to quarter ended December 31, 1998. Prepaid expenses and other assets were $652,000 at June 30, 1999 as compared to $503,000 at December 31, 1998. This increase of $149,000 or 29.6% is primarily the result of renewal of annual licenses, fees, and maintenance contracts which will be amortized throughout the year. At June 30, 1999, Laboratory Services had a total balance of restructuring accruals of $734,000 compared to a balance of $1,155,000 at December 31, 1998. The decrease of $421,000 is the result of settlement of pending litigation and certain payments made during the six months ended June 30, 1999. At June 30, 1999, Laboratory Services had a total loan balance owed to its financial lender of $7,147,000 compared to a total balance of $5,264,000 at December 31, 1998. The increase of $1,883,000 or 35.8% was the result increased borrowing during the six months ended June 30, 1999. Product Sales At June 30, 1999, net accounts receivable for Product Sales were $612,000. This $209,000 increase as compared to $403,000 at December 31, 1998 was primarily due to higher sales in the quarter ended June 30, 1999 as compared to the quarter ended December 31, 1998. Prepaid expenses and other assets were $76,000 at June 30, 1999 as compared to $21,000 at December 31, 1998. The increase of $55,000 is primarily the result of the renewal of certain annual expenses which will be amortized throughout the year. At June 30, 1999, the Product Sales segment had a total loan balance owed to its financial lender of $583,000, compared to a total balance of $756,000 owed at December 31, 1998. The net decrease of $173,000, or 22.8%, was the result of payments made during the six months ended June 30, 1999. Liquidity and Capital Resources Cash received from debt financing has been the primary source of funding for the working capital requirements of the Company. At June 30, 1999, the Company had checks written in excess of cash of $58,000 and available borrowings of $454,000. The Company believes that the aforementioned capital will be sufficient to fund the Company's planned operations through 1999. While there can be no assurance that the available capital will be sufficient to fund the future operations of the Company beyond 1999, the Company believes that consistent profitable earnings, as well as access to debt and equity, will be the primary basis for funding the operations of the Company for the long term. The Company continues to follow a plan which includes (i) continuing to aggressively monitor and control costs and (ii) increasing revenue from sales of the Company's products, services, and research and development contracts. There can be no assurance that costs can be controlled, revenues can be increased, financing may be obtained, acquisitions successfully consummated, or that the Company will continue to be profitable. Year 2000 The "Year 2000" issue arises from the fact that many computer systems rely on a two-digit date code to identify the year (e.g. 99 to represent 1999) and thus may not be able to differentiate between the year 2000 and the year 1900. If not corrected, systems processing date-dependent information may fail or create erroneous results, causing disruptions of operations, including, but not limited to, a temporary inability to process transactions, report results, send invoices, or engage in similar normal business activity. The Company has completed its assessment of its internal computer systems and has completed 85% of the testing and modifications required to a portion of its software so that its computer systems function properly with respect to dates in the year 2000 and beyond. The Company expects the remaining 15% of the testing and modifications to be completed during the third quarter. The Company presently believes that with these modifications to existing software and conversion to new software, the Year 2000 issue will not pose significant operational problems for its computer systems. The Company has initiated formal communication with all of its significant suppliers to determine the extent to which the Company is vulnerable to those third parties ability to resolve their own Year 2000 issues. As there can be no guarantee that the systems of other companies on which the Company relies will be timely converted or that a failure to convert or a conversion that is incompatible with the Company's system would not have an adverse effect on the Company's systems, the Company is developing contingency plans including alternate vendors and increased stock levels for all critical items. The Company anticipates completing the Year 2000 project prior to any adverse impact on its computer operating system, however, if such modifications and conversions are not made, or completed timely, the Year 2000 issue could have a material impact on the operations of the Company. The cost of the Year 2000 project is not expected to be material. Changes required to internally supported software are minor compared to the modifications performed in the normal course of business and the Company plans to use internal resources and delay other projects to complete these Year 2000 modifications. Updates to externally supported software are covered under existing service contracts or are not anticipated to have costs material in nature. The assessment of the impact, cost, and completion of the Year 2000 project is based on management's best estimates. Actual results could differ materially from those anticipated by factors including, but not limited to, the continued availability of certain resources, third party modification plans, and the ability to locate and correct all relevant computer codes. ITEM 2 CHANGES IN SECURITIES Inapplicable ITEM 3 DEFAULTS ON SENIOR SECURITIES. Inapplicable ITEM 4 SUBMISSION OF MATTERS TO A VOTE OF SECURITIES HOLDERS. Inapplicable ITEM 5 OTHER INFORMATION. Inapplicable ITEM 6 EXHIBITS AND REPORTS ON FORM 8-K. Exhibit 27: Financial Data Schedule SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Date: August 16, 1999 MEDTOX SCIENTIFIC, INC. By: /s/ Harry G. McCoy Harry G. McCoy, Chairman and President By: /s/ Richard J. Braun Richard J. Braun, Chief Executive Officer and Treasurer EX-27 2 EXHIBIT 27 (FDS)
5 1,000 6-MOS DEC-31-1999 JUN-30-1999 0 0 7703 246 1222 9407 13590 10793 25805 11367 0 0 0 437 11823 25805 16987 16987 11181 15711 0 0 375 901 0 901 0 0 0 901 0.31 0.31
-----END PRIVACY-ENHANCED MESSAGE-----